CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$233.56M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 5.64: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.83BUSDvs all stocks (USD)
Revenue (TTM)
164.01MUSDvs all stocks (USD)
Profit Margin
-40.23%vs Biotechnology peers
Beta
2.18xvs all stocks
52-Week Change
30.91%vs all stocks
Market Capitalization
2.83BUSDvs all stocks (USD)
Enterprise Value
2.11BUSDvs all stocks (USD)
Forward P/E
-6.00xvs Biotechnology peers
Price to Sales (TTM)
17.81xvs Biotechnology peers
Price to Book (MRQ)
2.42xvs Biotechnology peers
Enterprise to Revenue
12.86xvs Biotechnology peers
Enterprise to EBITDA
-6.04xvs Biotechnology peers
Profit Margin
-40.23%vs Biotechnology peers
Operating Margin
-337.81%vs Biotechnology peers
Return on Assets (TTM)
-15.76%vs Biotechnology peers
Return on Equity (TTM)
-5.77%vs Biotechnology peers
Revenue (TTM)
164.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.60USDUpdated Jul 18, 2026Quarterly Revenue Growth
324.90%vs Biotechnology peers
Gross Profit (TTM)
-240.93MUSDvs all stocks (USD)
EBITDA (TTM)
-349.25MUSDvs all stocks (USD)
Net Income (TTM)
-65.98MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
324.87%vs Biotechnology peers
Operating Cash Flow (TTM)
-369.73MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-233.56MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
139.74MUSDFY2025 · Dec 31, 2025Operating Income
-383.69MUSDvs all stocks (USD)
Pre-tax Income
-79.99MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-79.99MUSDFY2025 · Dec 31, 2025EBIT
-383.69MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-366.22MUSDFY2025 · Dec 31, 2025Research & Development
409.62MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
113.82MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8100USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8100USDFY2025 · Dec 31, 2025Basic Shares Outstanding
98.91MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
98.91MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-79.99MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-81.95MUSDFY2025 · Dec 31, 2025Free Cash Flow
-96.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
301.62MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-79.99MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
22.29MUSDFY2025 · Dec 31, 2025Stock-based Compensation
94.24MUSDFY2025 · Dec 31, 2025Other Non-cash Items
24.71MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-149.25MUSDFY2025 · Dec 31, 2025Capital Expenditures
-14.95MUSDFY2025 · Dec 31, 2025Net Acquisitions
255.07MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.21BUSDFY2025 · Dec 31, 2025Sale of Investments
848.23MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-121.44MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
470.51MUSDFY2025 · Dec 31, 2025Shares Outstanding
102.74MSharesUpdated Jul 18, 2026Float Shares
87.94MSharesUpdated Jul 18, 2026Shares Short
22.88MSharesUpdated Jul 18, 2026Short Ratio
9.65daysvs all stocks
Short % of Shares Outstanding
34.46%vs all stocks
% Held by Insiders
1.40%vs all stocks
% Held by Institutions
106.85%vs all stocks
Total Cash (MRQ)
1.21BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.17USDUpdated Jul 18, 2026Total Debt (MRQ)
250.82MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2154xvs Biotechnology peers
Current Ratio (MRQ)
16.99xvs Biotechnology peers
Book Value per Share (MRQ)
11.71USDUpdated Jul 18, 2026Total Assets
1.48BUSDvs all stocks (USD)
Total Current Assets
1.27BUSDFY2025 · Dec 31, 2025Total Liabilities
242.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
212.49MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
145.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
96.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
294.94MUSDFY2025 · Dec 31, 2025Other Short-term Investments
950.27MUSDFY2025 · Dec 31, 2025Accounts Payable
10.23MUSDFY2025 · Dec 31, 2025Short-term Debt
14.36MUSDFY2025 · Dec 31, 2025Deferred Revenue
6.66MUSDFY2025 · Dec 31, 2025Other Current Liabilities
12.40MUSDFY2025 · Dec 31, 2025Long-term Debt
139.76MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
6.13MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.02MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.64BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.24BUSDvs all stocks (USD)
52-Week Low
15.60USDUpdated Jul 18, 202652-Week High
38.26USDUpdated Jul 18, 202652-Week Change
30.91%vs all stocks
Beta
2.18xvs all stocks
50-Day MA
31.62USDUpdated Jul 18, 2026200-Day MA
28.04USDUpdated Jul 18, 2026Avg 10-Day Volume
2.53MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.46MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.4900USDUpdated Jul 18, 2026Other Income / Expense
259.97MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.64: safe zoneNotable
Altman Z-Score: 5.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$233.56M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -233,555,744Global P5: -219,013,500
Market cap is $2.83B, above the global median of $1.15BNotable
Market cap (USD): 2,832,264,761Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC